Huang Dajun, Li Yanwei, Zheng Xiaoyan, Hu Jinming, Tang Hanzhang, Yin Yongjun, Wu Zhou, Kong Lingqiu
Department of Cardiovascular Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Clinical Research Center for Acupuncture and Moxibustion in Sichuan province, Sichuan JinXin Xinan Women's and Children's Hospital, Chengdu, People's Republic of China.
J Pain Res. 2025 Jan 10;18:105-125. doi: 10.2147/JPR.S489880. eCollection 2025.
This systematic review aimed to compare the efficacy of various acupuncture dosages for Chronic Stable Angina (CSA) using randomized controlled trials (RCTs), addressing the unclear relationship between dosage and effectiveness despite acupuncture's potential.
We searched eight bibliographic databases from inception to October 31, 2024, evaluating RCTs comparing acupuncture to placebo or standard care for CSA patients, focusing on angina attack frequency as the primary outcome. Studies were categorized into high (HDG), moderate (MDG), and low (LDG) dosage groups based on acupuncture characteristics: the number of acupoints, total sessions, frequency per week, and the need for "Deqi".
Of the 807 citations screened, 16 studies (1240 patients) were included: 3 studies in LDG, 10 in MDG, and 3 in HDG. Acupuncture significantly reduced angina attacks compared to placebo (SMD, -0.51; 95% CI [-0.77, -0.25], = 0.0001, =62%), and standard care (SMD, -1.25, 95% CI [-1.89, -0.61], = 0.00001, =92%) without increasing adverse events. MDG showed a notable difference in reducing angina attacks (SMD, -0.60, 95% CI [-0.91, -0.29], = 0.001, =60%) while LDG and HDG did not. There is no difference in adverse events between groups. The evidence quality ranged from very low to moderate, and the results should be cautiously applied.
Acupuncture therapy effectively and safely alleviates CSA symptoms. Moderate dosage demonstrated the potential for better effects in reducing symptoms, suggesting optimal dosage considerations for future treatments.
CRD42022321547.
本系统评价旨在通过随机对照试验(RCT)比较不同针灸剂量治疗慢性稳定型心绞痛(CSA)的疗效,尽管针灸有潜在作用,但剂量与疗效之间的关系尚不明确。
我们检索了从数据库建立至2024年10月31日的八个文献数据库,评估比较针灸与安慰剂或标准护理对CSA患者疗效的RCT,重点关注心绞痛发作频率作为主要结局。根据针灸特征(穴位数量、总疗程、每周频率和得气需求)将研究分为高剂量组(HDG)、中剂量组(MDG)和低剂量组(LDG)。
在筛选的807篇文献中,纳入了16项研究(1240例患者):LDG组3项研究,MDG组10项研究,HDG组3项研究。与安慰剂相比,针灸显著减少了心绞痛发作(标准化均数差,-0.51;95%置信区间[-0.77,-0.25],P = 0.0001,I² = 62%),与标准护理相比也显著减少(标准化均数差,-1.25,95%置信区间[-1.89,-0.61],P = 0.00001,I² = 92%),且未增加不良事件。MDG组在减少心绞痛发作方面显示出显著差异(标准化均数差,-0.60,95%置信区间[-0.91,-0.29],P = 0.001,I² = 60%),而LDG组和HDG组则没有。各组之间不良事件无差异。证据质量从极低到中等不等,结果应谨慎应用。
针灸疗法有效且安全地缓解了CSA症状。中等剂量在减轻症状方面显示出更好效果的潜力,为未来治疗提示了最佳剂量考量。
PROSPERO注册号:CRD42022321547。